ATE254476T1 - 88kda tumorgener wachstumsfaktor und antagonisten - Google Patents

88kda tumorgener wachstumsfaktor und antagonisten

Info

Publication number
ATE254476T1
ATE254476T1 AT98926056T AT98926056T ATE254476T1 AT E254476 T1 ATE254476 T1 AT E254476T1 AT 98926056 T AT98926056 T AT 98926056T AT 98926056 T AT98926056 T AT 98926056T AT E254476 T1 ATE254476 T1 AT E254476T1
Authority
AT
Austria
Prior art keywords
antagonists
88kda
growth factor
tumorous growth
expression
Prior art date
Application number
AT98926056T
Other languages
English (en)
Inventor
Ginette Serrero
Original Assignee
Ginette Serrero
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ginette Serrero filed Critical Ginette Serrero
Application granted granted Critical
Publication of ATE254476T1 publication Critical patent/ATE254476T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT98926056T 1997-05-23 1998-05-22 88kda tumorgener wachstumsfaktor und antagonisten ATE254476T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86307997A 1997-05-23 1997-05-23
US08/991,862 US6309826B1 (en) 1997-05-23 1997-12-16 88kDa tumorigenic growth factor and antagonists
PCT/US1998/010555 WO1998052607A1 (en) 1997-05-23 1998-05-22 88kda tumorigenic growth factor and antagonists

Publications (1)

Publication Number Publication Date
ATE254476T1 true ATE254476T1 (de) 2003-12-15

Family

ID=27127743

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98926056T ATE254476T1 (de) 1997-05-23 1998-05-22 88kda tumorgener wachstumsfaktor und antagonisten

Country Status (10)

Country Link
US (3) US6309826B1 (de)
EP (2) EP1356824A3 (de)
AT (1) ATE254476T1 (de)
AU (1) AU7797898A (de)
CA (1) CA2290602C (de)
DE (1) DE69819911T2 (de)
DK (1) DK1011723T3 (de)
ES (1) ES2213906T3 (de)
PT (1) PT1011723E (de)
WO (1) WO1998052607A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309826B1 (en) * 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
US8512960B2 (en) * 1997-05-23 2013-08-20 A&G Pharmaceutical, Inc. 88kDa tumorigenic growth factor and antagonists
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US20030215445A1 (en) * 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6720159B1 (en) * 1997-12-16 2004-04-13 A&G Pharmaceutical, Inc. 88KDA tumorigenic growth factor and antagonists
US6872703B2 (en) 2000-06-07 2005-03-29 Ajinomoto Co., Inc. Insulin receptor-related receptor binding protein
AU2007229401B2 (en) * 2001-06-15 2011-10-06 A & G Pharmaceuticals, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic efffects of antiestrogen therapy
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
AU2003297217B2 (en) * 2003-02-26 2010-01-07 A & G Pharmaceuticals, Inc. Methods for increasing the proliferation of B cells
EP1644038A2 (de) * 2003-06-23 2006-04-12 A & G Pharmaceuticals, Inc. Zusammenetzungen und verfahren zur wiederherstellung der emfpindlichkeit von tumorzellen auf eine antitumorale therapie und einleitung von apoptose
EP1849480A3 (de) * 2003-06-23 2013-06-26 A & G Pharmaceutical, Inc. Zusammensetzungen und Verfahren zur Wiederherstellung der Empfindlichkeit von Tumorzellen gegen die Antitumorbehandlung und zur Induzierung von Apoptose
WO2005009217A2 (en) * 2003-07-21 2005-02-03 Medimmune, Inc. Diagnosis of pre-cancerous conditions using pcdgf agents
ES2426916T3 (es) 2003-08-01 2013-10-25 A & G Pharmaceutical, Inc. Composiciones y procedimientos para restaurar la sensibilidad al tratamiento con antagonistas de HER2
US20050244839A1 (en) * 2004-04-29 2005-11-03 Cheung Siu T Granulin-epithelin precursor (GEP) overexpression as a target for diagnosis, prognosis and treatment of hepatocellular carcinoma (HCC)
KR20070090156A (ko) * 2004-10-13 2007-09-05 에이 앤드 지 파마슈티컬즈, 인코포레이티드 오토크라인 성장 인자 수용체 및 방법
DE102005033237B4 (de) * 2005-07-15 2007-09-20 Siemens Ag Verfahren zur Bestimmung und Korrektur von Fehlorientierungen und Offsets der Sensoren einer Inertial Measurement Unit in einem Landfahrzeug
EP2037948B1 (de) * 2006-05-30 2016-04-13 Mayo Foundation For Medical Education And Research Erkennung und behandlung von demenz
EP2687223B1 (de) * 2006-05-30 2017-07-12 Mayo Foundation For Medical Education And Research Erkennung und Behandlung von Demenz
US8057579B2 (en) * 2008-11-10 2011-11-15 General Electric Company Method, apparatus, and system for acid gas removal
KR101229821B1 (ko) 2010-11-09 2013-02-05 가톨릭대학교 산학협력단 그래뉼린-에피테린 전구체 유전자의 발현을 억제하는 안티센스 및 이를 함유하는 약제학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
US6720159B1 (en) 1997-12-16 2004-04-13 A&G Pharmaceutical, Inc. 88KDA tumorigenic growth factor and antagonists
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US7091047B2 (en) 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6309826B1 (en) 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
DK1318837T3 (da) 2000-08-11 2005-01-10 Wyeth Corp Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
US7411045B2 (en) 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods

Also Published As

Publication number Publication date
CA2290602A1 (en) 1998-11-26
US20020061859A1 (en) 2002-05-23
EP1011723B1 (de) 2003-11-19
US6670183B2 (en) 2003-12-30
EP1356824A2 (de) 2003-10-29
EP1356824A3 (de) 2004-02-04
DE69819911T2 (de) 2004-09-02
DK1011723T3 (da) 2004-03-22
EP1011723A1 (de) 2000-06-28
CA2290602C (en) 2015-10-06
AU7797898A (en) 1998-12-11
US20040131618A1 (en) 2004-07-08
EP1011723A4 (de) 2001-12-05
US6309826B1 (en) 2001-10-30
ES2213906T3 (es) 2004-09-01
WO1998052607A1 (en) 1998-11-26
DE69819911D1 (de) 2003-12-24
US7592318B2 (en) 2009-09-22
PT1011723E (pt) 2004-04-30

Similar Documents

Publication Publication Date Title
ATE254476T1 (de) 88kda tumorgener wachstumsfaktor und antagonisten
DE69412807T2 (de) Einrichtung zur abgabe von elektrischen impulsen für die behandlung biologischer gewebe
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE69327231D1 (de) Kalzifizierungsverhütende behandlung für aldehydgegerbte biologische gewebe
FR12C0004I1 (de)
PT1232264E (pt) Gene fgf-21 humano e produtos da expressão do gene
EP0671920A4 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
DE59007513D1 (de) Anordnung zur Gewebestimulation.
DE59008148D1 (de) Anordnung zur Gewebestimulation.
DE69328025T2 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
DE3782214D1 (de) Mittel zur behandlung des scheidenmilieus.
GB2370750B (en) Method for treating fertilized chicken eggs and method for hatching the fertilized eggs
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
DE59004255D1 (de) Medizinisches gerät zur stimulation von gewebekontraktionen.
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE69108116D1 (de) Vorrichtung zur Stimulation lebenden Gewebes.
DE69813354T2 (de) Mittel zur Behandlung von Herzkrankheiten
DE69521281T2 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1011723

Country of ref document: EP